SCHEMBL2019158

SCHEMBL2019158

Nc1n[nH]c2cccc(C(=O)O)c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.54
PDPK1 O15530 2/20 0.54
KDR P35968 9/20 0.50
KIT P10721 5/20 0.50
FLT3 P36888 5/20 0.50
LCK P06239 3/20 0.50
CSF1R P07333 3/20 0.50
FGFR1 P11362 3/20 0.50
PRKACA P17612 3/20 0.50
ROCK1 Q13464 3/20 0.50
CDK2 P24941 3/20 0.50
AURKA O14965 3/20 0.50
AURKB Q96GD4 3/20 0.50
PLK4 O00444 2/20 0.50
JAK2 O60674 2/20 0.50
NTRK1 P04629 2/20 0.50
CDK1 P06493 2/20 0.50
LYN P07948 2/20 0.50
MET P08581 2/20 0.50
SRC P12931 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28192330 0.85 GAA (0.53) GAAPDPK1KDRKITFLT3
SCHEMBL22996547 0.81 GAA (0.50) GAAPDPK1KDRKITFLT3
SCHEMBL28497966 0.81 PARP1 (0.45) FLT3CDK2NAPRTKDM4ECYP3A4
SCHEMBL28503102 0.79 PARP1 (0.44) FLT3CDK2NAPRTKDM4ECYP3A4
SCHEMBL6284919 0.78 PARP1 (0.43) PDPK1KDRKITFLT3LCK
SCHEMBL29954027 0.78 PARP1 (0.43) PDPK1KDRKITFLT3LCK
SCHEMBL25337284 0.77 GAA (0.45) GAAPDPK1KDRKITFLT3
SCHEMBL545988 0.76 KDR (0.70) KDRKITFLT3LCKCSF1R
SCHEMBL13982513 0.76 PARP1 (0.51) NAPRTKDM4EPARP1
SCHEMBL16456826 0.74 KDR (0.66) KDRKITFLT3LCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968719-B2 Indazole derivatives as inhibitors of hormone sensitive lipase SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-06-28 US disclosed
US-20090215824-A1 INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE SENSITIVE LIPASE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-08-27 US disclosed
US-7528155-B2 Indazole derivatives as inhibitors of hormone sensitive lipase SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-05-05 US disclosed
US-20050197348-A1 Indazole derivatives as inhibitors of hormone sensitive lipase AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-09-08 US disclosed
US-4051252-A ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC BAYER AKTIENGESELLSCHAFT (DT) 1977-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215824-A1 INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE SENSITIVE LIPASE LIPE, PNLIP, CEL GAA 50/4885PDPK1 726/4885KDR 4671/4885
US-20050197348-A1 Indazole derivatives as inhibitors of hormone sensitive lipase LIPE, PNLIP, CEL GAA 50/4885PDPK1 726/4885KDR 4671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.